Skip to content

Study · Animal study (in vivo) · mouse · 2024

5 results

A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP

The Journal of pharmacology and experimental therapeutics17 Jan 2024Cited by 29 (Europe PMC)

PMID37739806 (opens in a new tab)PMCIDPMC10801787 (opens in a new tab)DOI10.1124/jpet.123.001733 (opens in a new tab)PepBankPUB-37739806
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mouse obesity and metabolic syndrome models, SLU‑PP‑332 increased energy expenditure.

    In plain wordsIn mice with obesity and metabolic syndrome, SLU‑PP‑332 increased energy use.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseEnergy expenditure
    Study

    mousen: not reported in source

    Diet-induced obese or ob/ob mice
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation.
    2 context sentences
    Summary · context
    Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome.
    Summary · context
    Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mouse obesity and metabolic syndrome models, SLU‑PP‑332 increased fatty acid oxidation.

    In plain wordsIn mice with obesity and metabolic syndrome, SLU‑PP‑332 increased fatty acid oxidation.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseFatty acid oxidation
    Study

    mousen: not reported in source

    Diet-induced obese or ob/ob mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation.
    2 context sentences
    Summary · context
    Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome.
    Summary · context
    Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mouse obesity and metabolic syndrome models, SLU‑PP‑332 decreased fat mass accumulation.

    In plain wordsIn mice with obesity and metabolic syndrome, SLU‑PP‑332 reduced fat accumulation.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseFat mass accumulation
    Study

    mousen: not reported in source

    Diet-induced obese or ob/ob mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These effects were accompanied by decreased fat mass accumulation.
    3 context sentences
    Summary · context
    SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation.
    Summary · context
    Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome.
    Summary · context
    Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mouse metabolic syndrome models, SLU‑PP‑332 reduced obesity.

    In plain wordsIn mice with metabolic syndrome, SLU‑PP‑332 reduced obesity.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseObesity
    Study

    mousen: not reported in source

    Diet-induced obese or ob/ob mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome.
    2 context sentences
    Summary · context
    Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome.
    Summary · context
    Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mouse metabolic syndrome models, SLU‑PP‑332 improved insulin sensitivity.

    In plain wordsIn mice with metabolic syndrome, SLU‑PP‑332 improved insulin sensitivity.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseInsulin sensitivity
    Study

    mousen: not reported in source

    Diet-induced obese or ob/ob mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome.
    2 context sentences
    Summary · context
    Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome.
    Summary · context
    Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.